Product Name: Carfilzomib
Form: Free base
CAS No: 868540-17-4
Molar Mass: 719.91
Chemical Formula: C40H57N5O7
Synonyms: Kyprolis, PR 171
Storage: Store at -20℃
Sequence: XLFL
Target: peptide epoxyketone class proteasome
Application:
Carfilzomib (CAS: 868540-17-4) is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. Its mechanism of action involves irreversibly binding to and inhibiting the chymotrypsin-like activity of the 20S proteasome, leading to the accumulation of misfolded proteins and ultimately inducing apoptosis in cancer cells. Carfilzomib is particularly effective in patients who have relapsed or become refractory to other treatment options. In pharmaceutical chemistry, the design and synthesis of carfilzomib and related proteasome inhibitors represent significant advancements in cancer therapy, offering targeted approaches to disrupt proteasome function and combat tumor progression. Moreover, ongoing research focuses on optimizing carfilzomib's pharmacokinetic properties and exploring its potential in combination therapies for various malignancies, highlighting its importance in the field of oncology.
Current Research:
Carfilzomib is a proteasome inhibitor used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. It is particularly effective in patients who have previously undergone other treatments like bortezomib but have not responded or have relapsed. Carfilzomib works by selectively inhibiting the 26S proteasome, a complex responsible for degrading damaged or unneeded proteins in cells. This inhibition leads to the accumulation of proteins within cancer cells, inducing stress and promoting cell death, which is particularly effective against malignant cells that are highly dependent on proteasomal activity for survival.
Mechanism of Action
Carfilzomib exerts its effects by irreversibly binding to the 20S core particle of the 26S proteasome, inhibiting its chymotrypsin-like activity. The proteasome plays a crucial role in degrading misfolded or excess proteins, maintaining cellular homeostasis. By inhibiting the proteasome, carfilzomib leads to the accumulation of polyubiquitinated proteins, which disrupts cellular function and triggers a variety of cellular stress responses. In cancer cells, particularly in multiple myeloma, this protein buildup induces apoptosis (programmed cell death) due to overwhelmed proteostasis. The drug is especially effective in rapidly dividing cancer cells, which have a higher demand for protein turnover.
Indications and Uses
Carfilzomib is indicated for the treatment of relapsed or refractory multiple myeloma, typically in combination with other chemotherapy agents such as lenalidomide or dexamethasone. It is administered intravenously and is typically given in cycles, with doses adjusted based on patient response and tolerability. Carfilzomib is particularly beneficial for patients who have previously been treated with bortezomib (another proteasome inhibitor) and have not responded to or have relapsed after initial treatment. It provides an option for these patients to help manage the disease and prolong survival.
Efficacy and Clinical Benefits
Clinical trials have demonstrated that carfilzomib significantly improves progression-free survival and overall response rates in patients with relapsed or refractory multiple myeloma. Studies have shown that combining carfilzomib with other agents such as lenalidomide or dexamethasone can lead to higher response rates compared to traditional therapies. In some cases, carfilzomib has led to deep and durable responses, improving patients' quality of life and prolonging survival. Its efficacy is particularly notable in patients with advanced disease who have limited treatment options, offering a critical tool for managing this challenging cancer.
Safety and Tolerability
Carfilzomib is generally well tolerated, though it can cause side effects. The most common adverse effects include fatigue, anemia, nausea, and peripheral neuropathy. More serious side effects include cardiovascular issues, such as hypertension, heart failure, and arrhythmias, which require careful monitoring. Infusion-related reactions, including fever, chills, and respiratory symptoms, can also occur but are generally manageable. In rare cases, carfilzomib can cause kidney toxicity, and kidney function should be monitored during treatment. Overall, the safety profile is considered manageable with proper monitoring, and the benefits in patients with relapsed or refractory multiple myeloma typically outweigh the risks.
Advantages and Limitations
The primary advantage of carfilzomib is its potent and selective inhibition of the proteasome, which is crucial for the survival of multiple myeloma cells. This makes it an effective therapy for relapsed or refractory cases of the disease. It offers a valuable alternative to bortezomib, especially in patients who have developed resistance to the latter. However, carfilzomib's intravenous administration and the potential for severe side effects, particularly related to the cardiovascular system and kidneys, may limit its use in certain populations. The need for careful patient monitoring during treatment is a key consideration.
Future Directions
Research into carfilzomib continues, with studies exploring its use in combination with other novel therapies, such as monoclonal antibodies and immune checkpoint inhibitors. These combinations may further improve treatment outcomes and reduce the risk of resistance. Additionally, ongoing clinical trials are investigating the potential of carfilzomib in earlier stages of multiple myeloma or in other hematologic malignancies, broadening its potential clinical applications. Efforts are also underway to develop oral formulations of carfilzomib or other proteasome inhibitors to improve patient convenience and adherence.
Reference:
Get a Quote
LinkPeptide
